CTOs on the Move

La Jolla Pharmaceutical Company

www.ljpc.com

 
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.ljpc.com
  • 4370 La Jolla Village Dr Ste 400
    San Diego, CA USA 92122
  • Phone: 858.207.4264

Executives

Name Title Contact Details

Similar Companies

Sonovion Pharmaceuticals

Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Collaborating Docs

We help nurse practitioners and physician assistants find amazing collaborative physicians in less than a week.

Chromocell, Corporation

Chromocell, Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.

Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow`s pipeline is led by SPI-62 in Phase 2 clinical development.